Inhibikase Therapeutics, Inc. Quarterly Share-based Payment Arrangement, Expense in USD from Q1 2020 to Q3 2024

Taxonomy & unit
us-gaap: USD
Description
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
Summary
Inhibikase Therapeutics, Inc. quarterly/annual Share-based Payment Arrangement, Expense history and growth rate from Q1 2020 to Q3 2024.
  • Inhibikase Therapeutics, Inc. Share-based Payment Arrangement, Expense for the quarter ending September 30, 2024 was $148K, a 14.1% increase year-over-year.
  • Inhibikase Therapeutics, Inc. Share-based Payment Arrangement, Expense for the twelve months ending September 30, 2024 was $354K, a 25.9% decline year-over-year.
  • Inhibikase Therapeutics, Inc. annual Share-based Payment Arrangement, Expense for 2023 was $500K, a 9.17% increase from 2022.
  • Inhibikase Therapeutics, Inc. annual Share-based Payment Arrangement, Expense for 2022 was $458K, a 70.1% decline from 2021.
  • Inhibikase Therapeutics, Inc. annual Share-based Payment Arrangement, Expense for 2021 was $1.53M, a 167% increase from 2020.
Share-based Payment Arrangement, Expense, Trailing 12 Months (USD)
Share-based Payment Arrangement, Expense, Quarterly (USD)
Share-based Payment Arrangement, Expense, YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2024 $354K $148K +$18.2K +14.1% Jul 1, 2024 Sep 30, 2024 10-Q 2024-11-14
Q2 2024 $336K $30.7K -$94.1K -75.4% Apr 1, 2024 Jun 30, 2024 10-Q 2024-08-14
Q1 2024 $430K $53.4K -$69.8K -56.7% Jan 1, 2024 Mar 31, 2024 10-Q 2024-05-15
Q4 2023 $500K $122K +$21.9K +21.8% Oct 1, 2023 Dec 31, 2023 10-K 2024-03-27
Q3 2023 $478K $130K +$28K +27.5% Jul 1, 2023 Sep 30, 2023 10-Q 2024-11-14
Q2 2023 $450K $125K -$7.92K -5.97% Apr 1, 2023 Jun 30, 2023 10-Q 2024-08-14
Q1 2023 $458K $123K +$44.00 +0.04% Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-15
Q4 2022 $458K $100K Oct 1, 2022 Dec 31, 2022 10-K 2024-03-27
Q3 2022 $102K Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-14
Q2 2022 $133K Apr 1, 2022 Jun 30, 2022 10-Q 2023-08-14
Q1 2022 $123K -$468K -79.2% Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-15
Q1 2021 $591K +$451K +323% Jan 1, 2021 Mar 31, 2021 10-Q 2022-05-16
Q1 2020 $140K Jan 1, 2020 Mar 31, 2020 10-Q 2021-05-17
* An asterisk sign (*) next to the value indicates that the value is likely invalid.